Current status of antibodies Myositis Profile in Inflammatory
Current status of antibodies (Myositis Profile) in Inflammatory myositis. Dr Chandrashekara S Medical Director Chan. Re Rheumatology & Immunology Center and Research
Introduction • Idiopathic inflammatory myopathies (IIM) are a group of systemic diseases characterized by an immune mediated attack on skeletal muscle • Characterized by �Proximal muscle weakness �Nonsuppurative inflammation of skeletal muscle �Accompanied by extramuscular manifestations �Arthritis, Skin lesions, ILD, Calcinosis, Nodules and vasculitis
Classification of Idiopathic Inflammatory Myopathy • Dermatomyositis ▫ Juvenile ▫ Adult • Polymyositis ▫ T cell mediated ▫ Eosinophilic ▫ Granulomatous • Inclusion body myositis • Overlap Syndrome ▫ Antisynthetase syndrome • Cancer associated myositis
What is the role of these AA Epiphenomena or pathognomonic ?
W h e r e o w n e d s d t
Prognosis- yes
How do we use it • • Ms X Muscle weakness from 3 month Joint pains Elevated SGPT/ OT normal GGT Elevated CPK ANA –ve Biopsy patient refusing
Case Ctd… • Myositis profile ▫ Shows positive Jo 1 +++
Case Ctd… • Evaluation for ILD • Management plans • Regular follow up for ILD
Myositis profile • Myositis specific antibodies are useful in diagnosis and therapeutic management of poly/dermatomyositis. • Anti Mi-2 is highly specific for dermatomyositis, found in 15 -30% • PM-Scl in 50 -70% of overlap syndromes with SSc • Jo-1 : prevalance is 25 -55%. Associated with interstitial lung fibrosis. • PL-7 & Pl-3 : prevalance is 36% and 3% respectively. Mi -2 Ku Jo-1 PL-12 PL-7 Ro-52 PM-Scl control
Thank you….
- Slides: 21